human menopausal gonadotropin

Human menopausal gonadotropin (hMG) is a purified biologic medication extracted from the urine of postmenopausal women, containing a mixture of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). It is primarily used in assisted reproductive technology (ART) to induce ovulation and stimulate the development of multiple ovarian follicles in women with infertility. In the specific context of research at Zekai Tahir Burak Women's Health Research and Education Hospital, hMG was evaluated in a Phase 4 clinical trial (NCT01365936) for its efficacy in ovarian stimulation among patients with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF). The study specifically focused on comparing urinary hMG to recombinant FSH (rFSH) to assess the prevention of ovarian hyperstimulation syndrome (OHSS), finding that hMG was associated with lower OHSS rates while maintaining comparable pregnancy outcomes.

Brand names

MenopurRepronexHumegonPergonalMenogon

Other names

MenotrophinMenotropinsUrinary human menopausal gonadotropinhMG-HP